Screening and early detection of prostate cancer: PSA and beyond

Poster Session 18

  • Location:
    Room Stockholm, North Hall (Level 1)
  • Chairs:
     F. Abdollah, Detroit (US)
     F.C. Hamdy, Oxford (GB)
     M.J. Roobol, Rotterdam (NL)
  • Aims and objectives of this session

    The session is aimed at addressing the multi-variable risk assessment to optimize the use of screening and early detection strategies in prostate cancer.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
An evaluation of a selective prostate cancer screening program using family history as a supplementary screening tool to PSA: Results from the ProtecT trial

By: Johnston T.1, Lamb A.1, Vowler S.2, Xiong T.1, Moore A.1, Holding P.3, Herbert P.1, Davis M.4, Lane A.4, Donovan J.4, Hamdy F.5, Neal D.1

Institutes: 1University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, 2Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom, 3University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, 4University of Bristol, School of Social and Community Medicine, Bristol, United Kingdom, 5University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom

At what age should a PSA-based screening program start? 20-year results from the Göteborg randomized population-based prostate cancer screening study

By: Carlsson S.1, Arnsrud Godtman R.2, Holmberg E.3, Lilja H.4, Månsson M.2, Stranne J.2, Hugosson J.2

Institutes: 1Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, 2Sahlgrenska Academy, Dept. of Urology, Gothenburg, Sweden, 3Sahlgrenska Academy, Dept. of Oncology, Gothenburg, Sweden, 4Memorial Sloan Kettering Cancer Center, Dept. of Surgery, Malmö, Sweden

Malignancies in male BRCA mutation carriers – results from a prospectively screened cohort of patients enrolled to a dedicated male BRCA clinic

By: Margel D.1, Mano R.1, Benjaminov O.2, Kedar I.3, Ozalvo R.1, Sela S.1, Ber Y.1, Baniel J.1

Institutes: 1Rabin Medical Center, Dept. of Urology, Petah Tikva, Israel, 2Rabin Medical Center, Dept. of Imaging, Petah Tikva, Israel, 3Rabin Medical Center, The Raphael Recanati Genetics Institute, Petah Tikva, Israel

Is further screening of Asian men with low baseline prostate-specific antigen levels (≤1.0 ng/ml) worthwhile?

By: Urata S., Kitagawa Y., Mizokami A.

Institutes: Kanazawa University, Dept. of Urology, Kanazawa, Japan

The use of prostate-specific antigen screening in purchased versus direct care settings: Data from the TRICARE military database

By: Gild P.1, Von Landenberg N.1, Cole A.1, Jiang W.2, Lipsitz S.2, Learn P.3, Sun M.1, Choueiri T.4, Nguyen P.5, Chun F.6, Fisch M.6, Kibel A.1, Menon M.7, Sammon J.7, Koehlmoss T.8, Haider A.2, Trinh Q-D.1

Institutes: 1Brigham and Women’s Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, 2Brigham and Women’s Hospital, Center for Surgery and Public Health, Boston, United States of America, 3Uniformed Services University of The Health Sciences, Dept. of Surgery, Bethesda, United States of America, 4Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Dept. of Medical Oncology, Boston, United States of America, 5Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, 6University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 7Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, 8Uniformed Services University of The Health Sciences, Dept. of Preventive Medicine and Biostatistics, Bethesda, United States of America

Prostate cancer screening in high risk families: Should PSA testing be performed yearly in first degree relatives with baseline PSA ≤1ng/ml?

By: Callerot P.1, Moineau M-P.2, Cussenot I.3, Baschet F.3, L’ Her J.1, Doucet L.1, Cancel-Tassin G.3, Cormier L.4, Mangin P.3, Cussenot O.5, Fournier G.1, Valeri A.1

Institutes: 1Brest University Hospital, Dept. of Urology, Brest, France, 2Brest University Hospital, Nuclear Medecine Laboratory, Brest, France, 3Tenon University Hospital, CeRePP (Centre De Recherche Sur Les Pathologies Prostatiques), Paris, France, 4Dijon University Hospital, Dept. of Urology, Dijon, France, 5Tenon University Hospital, Dept. of Urology, Paris, France

Risk of prostate-cancer death at 20 years stratified by midlife PSA and a panel of four kallikrein markers from a representative cohort of 11,506 healthy unscreened men aged 45-74

By: Sjoberg D.D.2, Vickers A.J.2, Assel M.2, Dahlin A3, Carlsson S.1, Poon B.Y.2, Ulmert D.1, Lilja H.G.1

Institutes: 1Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, 2Memorial Sloan Kettering Cancer Center, Dept. of Biostatistics, New York, United States of America, 3Lund University, Clinical Microbiology, Malmo, Sweden

Inclusion of mpMRI into the European Randomized study of Screening for Prostate Cancer (ERSPC) risk calculator: A new proposal to improve the accuracy of prostate cancer detection

By: Dell’Oglio P.1, Stabile A.1, Gandaglia G.1, Brembilla G.2, Maga T.1, Cristel G.2, Kinzikeeva E.1, Losa A.1, Esposito A.2, Cardone G.2, De Cobelli F.2, Del Maschio A.2, Gaboardi F.1, Montorsi F.1, Briganti A.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Vita-Salute University San Raffaele, Dept. of Radiology, Milan, Italy

Head-to-head comparison of commonly used international prostate cancer risk calculators for prostate biopsy

By: Pereira-Azevedo N.1, Verbeek J.1, Nieboer D.2, Steyerberg E.2, Roobol M.1

Institutes: 1Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, 2Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands

Outcomes of PSA-based prostate cancer screening among men using non-steroidal anti-inflammatory drugs

By: Murtola T.1, Vettenranta A.2, Talala K.3, Taari K.4, Stenman U.-H.5, Tammela T.1, Auvinen A.6

Institutes: 1Tampere University Hospital, Dept. of Urology, Tampere, Finland, 2University of Tampere, School of Medicine, Tampere, Finland, 3Finnish Cancer Registry, Dept. of Research, Helsinki, Finland, 4Helsinki University, School of Medicine, Helsinki, Finland, 5Helsinki University Hospital, Dept. of Biochemistry, Helsinki, Finland, 6University of Tampere, School of Health Sciences, Tampere, Finland

Decreasing screening efficacy with increasing age: Results from a population-based screening trial - Swiss ERSPC (Aarau)

By: Prause L.1, Wyler S.1, Möltgen T.1, Huber A.2, Grobholz R.3, Manka L.4, Recker F.1, Kwiatkowski M.1

Institutes: 1Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, 2Cantonal Hospital Aarau, Dept. of Laboratory Medicine, Aarau, Switzerland, 3Cantonal Hospital Aarau, Dept. of Pathology, Aarau, Switzerland, 4Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany

Stage distribution of prostate cancer at a tertiary care oncology centre in India - reflections of an unscreened population

By: Prakash G.1, Bakshi G.1, Shinde R.2, Bhamre R.2, Murthy V.3, Rent E.4, Pal M.1, Mahantshetty U.3, Menon S.5

Institutes: 1Tata Memorial Hospital, Dept. of Surgical Oncology(urooncology), Mumbai, India, 2Tata Memorial Hospital, Dept. of Surgical Oncology, Mumbai, India, 3Tata Memorial Hospital, Dept. of Radiation Oncology, Mumbai, India, 4AJ Shetty Hospital, Dept. of Surgical Oncology, Mangalore, India, 5Tata Memorial Hospital, Dept. of Surgical Pathology, Mumbai, India

* 246
The diverse genomic landscape of low-risk prostate cancer

By: Cooperberg M.1, Erho N.2, Chan J.3, Feng F.3, Cowan J.3, Simko J.3, Ong K.2, Alshalalfa M.4, Kolisnik T.2, Margrave J.2, Aranes M.2, Du Plessis M.2, Buerki C.4, Zhao S.2, Tenggara I.3, Davicioni E.2, Carroll P.3

Institutes: 1University of California, Dept. of Urology, San Francisco, United States of America, 2GenomeDx, San Diego, United States of America, 3UCSF, Dept. of Urology, San Francisco, United States of America, 4GenomeDx, , San Diego, United States of America

* 247
A positive digital rectal examination (DRE) does not predict prostate cancer in 45 yr old men - results from the German risk-adapted PCA Screening Trial (PROBASE)

By: Arsov C.1, Becker N.2, Herkommer K.3, Gschwend J.3, Imkamp F.4, Kuczyk M.4, Hadaschik B.5, Hohenfellner M.5, Siener R.6, Kristiansen G.7, Antoch G.8, Albers P.1

Institutes: 1University of Düsseldorf, Dept. of Urology, Düsseldorf, Germany, 2German Cancer Research Center Heidelberg, Division of Cancer Epidemiology (C020), Heidelberg, Germany, 3Technische Universitaet Muenchen, Dept. of Urology, Munich, Germany, 4Hanover Medical School, Dept. of Urology, Hanover, Germany, 5University of Heidelberg, Dept. of Urology, Heidelberg, Germany, 6University of Bonn, Dept. of Urology, Bonn, Germany, 7University of Bonn, Dept. of Pathology, Bonn, Germany, 8University of Düsseldorf, Dept. of Diagnostic and Interventional Radiology, Düsseldorf, Germany